Patents Issued in November 25, 2021
  • PHYTONADIONE COMPOSITIONS AND RELATED METHODS
    Publication number: 20210361593
    Abstract: Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.
    Type: Application
    Filed: August 3, 2021
    Publication date: November 25, 2021
    Inventors: Phanesh Koneru, Sreerarama Murthy Mallipeddi, Jonathan E. Sterling
  • EPINEPHRINE SPRAY FORMULATIONS
    Publication number: 20210361594
    Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 25, 2021
    Inventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
  • EPINEPHRINE SPRAY FORMULATIONS
    Publication number: 20210361595
    Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 25, 2021
    Inventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
  • LASOFOXIFENE TREATMENT OF BREAST CANCER
    Publication number: 20210361596
    Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 25, 2021
    Inventors: Kaitlyn Andreano, Ching-yi Chang, Donald P. McDonnell, Stephanie L. Gaillard
  • Synthesis of Ibuprofen Hybrid Conjugates as Anti-Inflammatory and Analgesic Agents
    Publication number: 20210361597
    Abstract: Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 25, 2021
    Applicant: Augusta University Research Institute, Inc.
    Inventor: Siva PANDA
  • COMPOUNDS FOR PREVENTION AND TREATMENT OF POST-INTENSIVE CARE COGNITIVE DYSFUNCTION AND COGNITIVE DYSFUNCTION RESULTING FROM RESPIRATORY DISTRESS
    Publication number: 20210361598
    Abstract: Presented herein, in certain aspects, are methods of preventing, reducing, delaying and treating Post-Intensive Care Cognitive Dysfunction (PICCD) by administering a compound disclosed herein to a subject prior to, during and/or after a stay in an ICU, intubation or connection to a ventilator. Also presented herein, in certain aspects, are methods of treating, preventing, inhibiting, reducing the severity of, or delaying the onset of a cognitive impairment or a cognitive disorder resulting from, or caused by respiratory distress.
    Type: Application
    Filed: April 28, 2021
    Publication date: November 25, 2021
    Inventors: Jesus Ernesto VILLAFRANCA, Charles KISSINGER
  • CARMUSTINE FORMULATION
    Publication number: 20210361599
    Abstract: The present invention relates to a composition comprising nitrosourea and pharmaceutically acceptable excipients. In particular, the present invention relates to novel drug delivery systems of carmustine such as nano-suspension and micro-emulsion and its use for the treatment of cancer by intravenous administration. Also provided are methods for preparation of such novel drug delivery systems.
    Type: Application
    Filed: March 30, 2019
    Publication date: November 25, 2021
    Applicant: EMCURE PHARMACEUTICALS LIMITED
    Inventors: Deepak Pragjibhai Gondaliya, Hiren Pravinbhai Patel, Haresh Ishwarbhai Patel, Mukund Keshav Gurjar
  • METHODS FOR INDUCING CHONDROGENESIS
    Publication number: 20210361600
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes using intra-articular administration.
    Type: Application
    Filed: April 23, 2018
    Publication date: November 25, 2021
    Inventors: Peter G. SCHULTZ, Arnab K. CHATTERJEE, Timothy M. WRIGHT, John WISLER, Vadim KLYUSHNICHENKO
  • GHB DOSING
    Publication number: 20210361601
    Abstract: Provided herein are methods of administering GHB formulations for the treatment of narcolepsy and other conditions.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Applicant: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventor: Franck SKOBIERANDA
  • DOSING METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS
    Publication number: 20210361602
    Abstract: The invention provides methods and compositions for local administration of therapeutic agents to the rectum or colon, such as by enema. The methods and compositions are useful for treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: May 22, 2020
    Publication date: November 25, 2021
    Inventors: Ravinder D. Pamnani, Sidhartha Ranjit Sinha, Karolin Julia Jarr, Navdeep Kaur
  • METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY
    Publication number: 20210361603
    Abstract: The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; or combination(s) thereof.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 25, 2021
    Applicants: New York University, Massachusetts Institute Of Technology
    Inventors: Thales PAPAGIANNAKOPOULOS, Tyler JACKS, Rodrigo ROMERO
  • Methods and Compositions For Enhancing Synthesis Secretion and Transport of Collagen to Increase Wound Strength
    Publication number: 20210361604
    Abstract: A method for, and medicinal composition for, treatment of mammalian cells for enhancing synthesis, secretion and transport of collagen to increase wound strength, that includes magnesium pyruvate; calcium pyruvate; L proline; citrulline: and a liquid carrier.
    Type: Application
    Filed: May 19, 2020
    Publication date: November 25, 2021
    Inventor: Alain Martin
  • FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20210361605
    Abstract: Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.
    Type: Application
    Filed: December 29, 2020
    Publication date: November 25, 2021
    Inventors: Roger Schofield Newton, Noah Rosenberg, Diane Elaine MacDougall
  • COMPOSITION FOR TREATMENT OF DRY EYE DISEASE AND MEIBOMIANITIS
    Publication number: 20210361606
    Abstract: The present application relates to compositions for treatment of eye disorders, particularly for treatment of dry eye disease (DED) and meibomianitis, wherein the composition comprises very long chain polyunsaturated fatty acids. Further, the invention provides a method for treatment of DED and meibomianitis of a subject, comprising administering to the subject a composition comprising very long chain polyunsaturated fatty acids derived from natural oils. The compositions for use are suitable for oral and local applications.
    Type: Application
    Filed: June 19, 2019
    Publication date: November 25, 2021
    Applicant: Epax Norway AS
    Inventors: Harald BREIVIK, Harald SVENSEN, Iren Merete Skjåstad STOKNES
  • COMBINATION METHODS AND COMPOSITIONS INCLUDING SLEEP THERAPEUTICS FOR TREATING MOOD
    Publication number: 20210361607
    Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.
    Type: Application
    Filed: August 28, 2020
    Publication date: November 25, 2021
    Inventor: Seth Feuerstein
  • STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF
    Publication number: 20210361608
    Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
    Type: Application
    Filed: May 23, 2021
    Publication date: November 25, 2021
    Applicant: Sol-Gel Technologies Ltd.
    Inventors: Ofer TOLEDANO, Karine NEIMANN, Danil FINKEL-MOISEEV, Maya ERLICH, Dorit MARCO
  • METHODS AND COMPOSITIONS FOR REDUCING ADIPOCYTE NUMBERS
    Publication number: 20210361609
    Abstract: A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 25, 2021
    Inventors: Shih-Horng Su, Tina Howden
  • COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS
    Publication number: 20210361610
    Abstract: A compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and one or more monovalent cations such as Na+ useful for the treatment of hypertension and/or heart failure.
    Type: Application
    Filed: August 5, 2021
    Publication date: November 25, 2021
    Inventors: Lili FENG, Sven Erik GODTFREDSEN, Paul Allen SUTTON, Mahavir PRASHAD, Michael J. GIRGIS, Bin HU, Yugang LIU, Thomas J. BLACKLOCK, Piotr Henryk KARPINSKI
  • TREATMENT OF DISORDERS WITH TASIMELTEON
    Publication number: 20210361611
    Abstract: Tasimelteon improves sleep in individuals experiencing an advance in established bedtime.
    Type: Application
    Filed: March 4, 2019
    Publication date: November 25, 2021
    Inventors: Vasilios POLYMEROPOULOS, Christos POLYMEROPOULOS, Changfu XIAO, Mihael H. POLYMEROPOULOS
  • SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF
    Publication number: 20210361612
    Abstract: There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.
    Type: Application
    Filed: October 15, 2019
    Publication date: November 25, 2021
    Inventors: Amnon Vardi, Nimrod Vardi, Omer Vardi
  • AUTOMATED IOT DEVICE CONFIGURATION USING USER PROFILE
    Publication number: 20210361613
    Abstract: The invention relates to a liquid composition comprising a combination of ?9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and an oral delivery system, methods of treating pain, inflammation and/or anxiety in a subject and methods of controlling a heart rate of a subject comprising orally administering the liquid composition, as well as downregulating or upregulating expression of particular related genes.
    Type: Application
    Filed: June 14, 2019
    Publication date: November 25, 2021
    Inventors: Layton Patrick MILLS, Margaret Ann CURTIS, Rayson TAN
  • ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
    Publication number: 20210361614
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Application
    Filed: March 5, 2021
    Publication date: November 25, 2021
    Inventor: Ofir MORENO
  • AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM
    Publication number: 20210361615
    Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomomi UENO, Tomoko DEGUCHI, Atsuko ONODA
  • AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM
    Publication number: 20210361616
    Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tomomi UENO, Tomoko Deguchi, Atsuko Onoda
  • ASCORBIC ACID FORMULATION
    Publication number: 20210361617
    Abstract: An object of the present invention is to provide an ascorbic acid formulation that can be prepared by a simple method, and that has a reduced unpleasant taste and coloration. The inventors found that an ascorbic acid formulation that is in the form of a water-in-oil type emulsion, that comprises an aqueous phase with a pH of 4 or more and an average particle size of 300 nm or less, and that has a mass ratio of water/ascorbic acid of 0.05 to 0.40 has a reduced unpleasant taste and coloration; and accomplished the present invention. Additionally, the present invention can be prepared by a simple method.
    Type: Application
    Filed: January 28, 2019
    Publication date: November 25, 2021
    Inventors: Arata HASHIMOTO, Masaharu KATO
  • TRIPLET COMBINATION FORMULATIONS AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20210361618
    Abstract: Disclosed herein are compositions comprising ETC-1002; Ezetimibe; a statin; and one or more pharmaceutical excipients or carriers. Also disclosed herein are methods for using said composition. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia and/or dyslipidemias in a subject.
    Type: Application
    Filed: February 8, 2018
    Publication date: November 25, 2021
    Inventors: Narendra Lalwani, Diane MacDougall
  • COMPOSITION FOR PREVENTING OR TREATING SARS CORONAVIRUS 2 INFECTION DISEASE
    Publication number: 20210361619
    Abstract: Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 25, 2021
    Inventors: Jong Sun Jung, Jong Hui Hong, Dong Myung Kim, Bong Hwan Park, Young Bae Ryu, Hyung Jun Kwon, In Chul Lee, Ji Young Park
  • SLEEP ENHANCEMENT WITH A PROTEIN-BOUND TRYPTOPHAN AND MELATONIN MIXTURE
    Publication number: 20210361620
    Abstract: A composition comprising, preferably, at least partially defatted meal from a plant source containing protein-bound tryptophan that, preferably, has a higher tryptophan source than said plant source, a melatonin component, and a pharmaceutically-acceptable diluent or carrier therefor for enhancing sleep quality and duration in a mammal. In some embodiments, the composition includes a carbohydrate. The invention provides a method of enhancing sleep quality in a mammal having a composition described above.
    Type: Application
    Filed: August 29, 2019
    Publication date: November 25, 2021
    Inventor: Craig J. HUDSON
  • Compositions and Methods for Reducing Weight Gain
    Publication number: 20210361621
    Abstract: The present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing Lactobacillus reuterii bacteria as a probiotic to reduce weight gain or to induce weight loss, particularly for subjects receiving an antibiotic or xenobiotic treatment.
    Type: Application
    Filed: August 3, 2021
    Publication date: November 25, 2021
    Inventors: John Richard Kirby, Orlando Grajo De Leon
  • BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA
    Publication number: 20210361622
    Abstract: The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
    Inventors: Chan Mi JOUNG, Sun Gwan HWANG, Ji Won LEE, Young Koo JANG
  • THIOUREYLENE LIQUID COMPOSITIONS
    Publication number: 20210361623
    Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.
    Type: Application
    Filed: August 2, 2021
    Publication date: November 25, 2021
    Inventors: Louise Reynolds, Manish Umrethia
  • USE OF A BISAMIDE DERIVATIVE OF MALONIC ACID FOR TREATING ALLERGIC AND OTHER DISEASES IN HUMANS AND ANIMALS
    Publication number: 20210361624
    Abstract: The invention relates to the therapy of diseases associated with the activity of histamine receptors, in particular for the treatment of allergic diseases, preferably the therapy of perennial and persistent allergic rhinitis, itch, as well as a number of other diseases associated with the activity of histamine receptor type 3 and/or 4, using compound N,N?-bis(2-(1H-imidazol-5-yl)ethyl)malonamide. This compound, as well as pharmaceutically acceptable salts, hydrates, or solvates thereof, is an antagonist of histamine receptor type 3 and/or 4. The invention also relates to pharmaceutical compositions containing a therapeutically effective amount of Compound I.
    Type: Application
    Filed: May 22, 2019
    Publication date: November 25, 2021
    Applicant: PHARMENTERPRISES ALLERGY LLC
    Inventor: Vladimir Evgenievich NEBOLSIN
  • COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA
    Publication number: 20210361625
    Abstract: Compositions for treating presbyopia may include active pharmaceutical ingredients of pilocarpine HCl, phenylephrine HCl, pheniramine maleate, and ketorolac tromethamine. Other ingredients may include boric acid, polyethylene glycol, propylene glycol, and BAK (benzalkonium chloride). The pilocarpine HCl may be in a range of 0.1% to 2%. The phenylephrine HCl may be in a range of 0.1% to 1.5%. The pheniramine maleate may be in a range of 0.07% to 0.35%. The ketorolac tromethamine may be in a range of 0.01% to 0.6%. The boric acid may be in a range of 0.5% to 1.5%. The polyethylene glycol may be in a range of 0.1% to 1%. The propylene glycol may be in a range of 0.1% to 1%. The BAK may be in a range of 0.005% to 0.01%. The solvent may be mostly water.
    Type: Application
    Filed: June 9, 2021
    Publication date: November 25, 2021
    Inventors: Anthony SAMPIETRO, Damien GOLDBERG, Amy FROST, Brian HOLDORF
  • CRYSTALLINE PRODUCT
    Publication number: 20210361626
    Abstract: The present invention provides a molecular complex of binimetinib, which is binimetinib dimethylsulfoxide (DMSO) solvate. It is also an object of the present invention to provide a molecular complex of binimetinib which is a crystalline molecular complex of binimetinib and citric acid. The present invention also relates to methods for the preparation of these molecular complexes.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Inventors: Amanda BUIST, Thierry BONNAUD, Richard EDWARDS, Adam PATTERSON, Mark WRIGHT
  • IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS
    Publication number: 20210361627
    Abstract: The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of some sarcomas, preferably in the treatment and/or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof.
    Type: Application
    Filed: October 23, 2018
    Publication date: November 25, 2021
    Inventors: Ryan David Roberts, Laura Brandolini
  • 2-OXOTHIAZOLE COMPOSITIONS FOR TREATMENT OF FIBROTIC DISEASE
    Publication number: 20210361628
    Abstract: A compound of formula (I), (I) wherein R10 is H or C1-6 alkyl such as Me; R2 is H, —(CH2)pCOOH, —(CH2)pCON(R5)2 or —(CH2)pCOOC1-6alkyl; each R5 is H or C1-6 alkyl; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C7-12arylalkyl, C2-12 alkenyl; OC1-12 alkyl, SC1-12 alkyl, OC2-12 alkenyl, C1-12 alkyl group, a C6-14 aryl group, —OC1-10alkyl-O—C1-10alkyl, —C1-10alkyl-O—C1-10alkyl, OAr2, O(CH2)qAr2, SAr2 or S(CH2)qAr2; wherein Ar2 is phenyl, optionally substituted with one or more of halo, trihalo methyl, C1-10-alkoxy, or C1-10 alkyl; p is 0 to 3; q is 1 to 3, preferably 1 n is 1 to 4; or a salt, ester, solvate, N-oxide, or prodrug thereof, e.g. a salt thereof; for use in the treatment or prevention of a fibrotic disease.
    Type: Application
    Filed: April 24, 2019
    Publication date: November 25, 2021
    Inventors: Astrid J. Feuerherm, Berit Johansen
  • THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES
    Publication number: 20210361629
    Abstract: Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 25, 2021
    Inventor: Gerard R. COLCA
  • COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND METFORMIN AND USE THEREOF FOR TREATING NEOPLASTIC DISEASES
    Publication number: 20210361630
    Abstract: A formulation for treating neoplastic diseases, including post-transplant malignancies, genetically-driven neoplasia associated with mTORC1 hyperactivation, and a viral associated malignancy comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neoplastic diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1.
    Type: Application
    Filed: August 3, 2021
    Publication date: November 25, 2021
    Inventor: Jeffrey M. Melin
  • N-methyl-D-aspartic Acid Receptor Modulators
    Publication number: 20210361631
    Abstract: A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc.
    Type: Application
    Filed: February 9, 2019
    Publication date: November 25, 2021
    Inventors: Dennis Liotta, Stephen F. Traynelis, David Menaldino, Matthew Epplin
  • BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT
    Publication number: 20210361632
    Abstract: A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Inventor: Michael Strupp
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210361633
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20210361634
    Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 25, 2021
    Inventors: Neil J. Hayward, Bertrand L. Chenard, Yuelian Xu, Philipp Erik Schneggenburger, Matteo Placido Placidi, Wendy Mercer Geil, Gonto Johns., III
  • METHODS FOR TREATING MUSCULAR DYSTROPHIES
    Publication number: 20210361635
    Abstract: Provided herein are methods for treating and preventing a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need thereof, comprising administering to the subject a compound that increases sarcospan. Also provided herein are pharmaceutical compositions comprising a compound that increases sarcospan, or a pharmaceutically acceptable salt or ester thereof, useful for the treatments described herein.
    Type: Application
    Filed: June 5, 2019
    Publication date: November 25, 2021
    Inventors: Rachelle H. Crosbie, Cynthia Shu
  • FUSED RING COMPOUND HAVING UREA STRUCTURE
    Publication number: 20210361636
    Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.
    Type: Application
    Filed: July 3, 2019
    Publication date: November 25, 2021
    Inventors: Tsuyoshi NAKAMURA, Mayuko AKIU, Takashi TSUJI, Jun TANAKA, Koji TERAYAMA, Mika YOKOYAMA, Anthony B. PINKERTON, Edward Hampton SESSIONS
  • PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20210361637
    Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: October 24, 2019
    Publication date: November 25, 2021
    Inventors: Joerg P. HEHN, Andreas BLUM, Oliver HUCKE, Stefan PETERS
  • FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES
    Publication number: 20210361638
    Abstract: The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 ?g to about 250 ?g, to a subject in need thereof.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 25, 2021
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte
  • SOLID COMPOSITIONS OF ACTIVES, PROCESSES FOR PREPARING SAME AND USES OF SUCH SOLID COMPOSITIONS
    Publication number: 20210361639
    Abstract: The present invention provides a solid composition comprising nanoparticles comprising at least one water-insoluble active and at least one oil, dispersed within a water-soluble mixture of at least one hydrophilic polymer and at least one surfactant. Process for preparing such solid compositions and aqueous dispersions of such compositions are also provided.
    Type: Application
    Filed: March 4, 2019
    Publication date: November 25, 2021
    Inventors: Steven Paul Rannard, Andrew Owen, Alison Savage, Lee Tatham, Andrew Dwyer, Helen Box, Joanne Sharp, Samantha Ashcroft
  • BETEL QUID CESSATION THERAPY WITH NICOTINE AND PILOCARPINE
    Publication number: 20210361640
    Abstract: Provided herein are compositions comprising nicotine, or a salt thereof, and pilocarpine, or a salt thereof, useful for reducing the use of betel quid and/or achieving betel quid cessation (e.g., replacement therapy). Also provided herein are methods of using the compositions in reducing the risk of developing or reducing the progression of a disease (e.g., cancer, oral disease, neurological disease, or painful condition). Compositions of the present invention may be administered to a subject with an addiction, e.g., a betel quid addiction, areca nut addiction, and/or nicotine addiction.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 25, 2021
    Inventors: Roger L. Papke, Samuel Leslie Glatman
  • Inhibitors of DUX4 Induction for Regulation of Muscle Function
    Publication number: 20210361641
    Abstract: Disclosed are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy. In some cases, the methods and compositions involve the use of kinase inhibitors include Src, Syk, Abl, Tie, Flt, ErbB, Trk, PRKDC, and Yes families to repress DUX4 expression in muscle cells. Further disclosed are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy.
    Type: Application
    Filed: July 14, 2021
    Publication date: November 25, 2021
    Inventors: Amanda Rickard, Uli Schmidt, Alexander Kiselyov
  • WASP-PROTECTING SMALL MOLECULES, COMPOSITIONS, METHODS AND USES THEREOF IN THE TREATMENT OF INNATE AND ACQUIRED IMMUNE-RELATED DISORDERS OR CONDITIONS
    Publication number: 20210361642
    Abstract: The present invention provides specific small molecule compounds that modulate degradation and stability of Wiskott-Aldrich Syndrome protein (WASp), methods and uses thereof in innate and acquired immune-related disorders or conditions, specifically, in primary and secondary immune-deficiencies.
    Type: Application
    Filed: July 26, 2021
    Publication date: November 25, 2021
    Inventor: Mira BARDA-SAAD